Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Core Insights - Autolus Therapeutics plc will host an R&D investor event on April 23, 2025, to discuss updates on its clinical pipeline and expansion plans [1][2] Group 1: Company Overview - Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing next-generation T cell therapies for cancer and autoimmune diseases [4] - The company utilizes proprietary T cell programming technologies to create targeted and effective therapies [4] - Autolus has an FDA-approved product, AUCATZYL, and is developing additional candidates for hematological malignancies, solid tumors, and autoimmune diseases [4] Group 2: Upcoming Event Details - The R&D investor event will take place in New York City at 8:30am EDT / 13:30pm BST [1] - The company will present initial data from the CARLYSLE Phase 1 trial in systemic lupus erythematosus and discuss plans for expansion in autoimmune diseases [2] - A webcast of the presentation will be available on the company's website, with a replay archived for 90 days [3]